Titles
- Community health centers: growing importance in a changing health care system1
- Comparative effectiveness research: Patient-Centered Outcomes Research Institute and HHS continue activities and plan new efforts : report to Congressional committees1
- Comparing health insurance reform options: from "building on the ACA" to single payer1
- Competing demands: operational imperatives for the California Health Benefit Exchange1
- Competition and choice in the health insurance marketplaces, 2014-2015: impact on premiums1
- Compliance policy for certain compounding of oral oxitriptan (5-HTP) drug products for patients with tetrahydrobiopterin (BH4) deficiency: immediately in effect guidance for industry1
- Compounded drug products that are essentially copies of a commercially available drug product under Section 503A of the Federal Food, Drug, and Cosmetic Act1
- Compounded drug products that are essentially copies of approved drug products under Section 503B of the Federal Food, Drug, and Cosmetic Act1
- Compounding certain ibuprofen oral suspension products under section 503B of the Federal Food, Drug, and Cosmetic Act1
- Considerations for a local health insurance option in Medicaid non-expansion states1
- Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products: guidance for industry1
- Continuing progress on the opioid epidemic: the role of the Affordable Care Act1
- Cost and coverage implications of five options for increasing marketplace subsidy generosity1
- Could a public health insurance option lead to more competitive markets?1
- Coverage and care pathways for people with HIV: a new baseline1
- Coverage during a crisis: insured rate for Californians hits historic high in first year of COVID-19 pandemic1
- Coverage options for Mississippians after implementation of the ACA1
- Creating a culture for innovation and risk taking in transformative times1
- Creating seamless coverage transitions between Medicaid and the exchanges1
- Cybersecurity in medical devices: refuse to accept policy for cyber devices and related systems under section 524B of the FD&C Act : guidance for industry and Food and Drug Administration staff1